Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells

Por Ruella, Marco, Barrett, David M, Kenderian, Saad S, Shestova, Olga, Hofmann, Ted J, Scholler, John, Lacey, Simon F, Melenhorst, Jan J, Nazimuddin, Farzana, Perazzelli, Jessica, Christian, David A, Hunter, Christopher A, Porter, David L, June, Carl H, Grupp, Stephan A, Gill, Saar
Publicado no J Immunother Cancer (2015)

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Por Bhoj, Vijay G., Arhontoulis, Dimitrios, Wertheim, Gerald, Capobianchi, James, Callahan, Colleen A., Ellebrecht, Christoph T., Obstfeld, Amrom E., Lacey, Simon F., Melenhorst, Jan J., Nazimuddin, Farzana, Hwang, Wei-Ting, Maude, Shannon L., Wasik, Mariusz A., Bagg, Adam, Schuster, Stephen, Feldman, Michael D., Porter, David L., Grupp, Stephen A., June, Carl H., Milone, Michael C.
Publicado no Blood (2016)

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Por Ruella, Marco, Barrett, David M., Kenderian, Saad S., Shestova, Olga, Hofmann, Ted J., Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F., Melenhorst, Jan J., Morrissette, Jennifer J.D., Christian, David A., Hunter, Christopher A., Kalos, Michael, Porter, David L., June, Carl H., Grupp, Stephan A., Gill, Saar
Publicado no J Clin Invest (2016)